Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 11/20 | 0.62 |
| ▸ | MTNR1B | P49286 | 11/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | HTR2C | P28335 | 9/20 | 0.41 |
| ▸ | HTR2A | P28223 | 7/20 | 0.41 |
| ▸ | HTR2B | P41595 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL28396882 | 0.98 | MTNR1A (0.60) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL12056685 | 0.88 | MTNR1A (0.67) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL23944988 | 0.84 | MTNR1B (0.61) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL23944947 | 0.84 | MTNR1B (0.61) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL340076 | 0.82 | MTNR1A (0.62) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL30892245 | 0.82 | MTNR1A (0.62) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL28357968 | 0.82 | MTNR1A (0.65) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL11917773 | 0.82 | MTNR1A (0.62) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL340075 | 0.82 | MTNR1A (0.62) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL28361707 | 0.82 | MTNR1A (0.65) | MTNR1AMTNR1BABCB11SIGMAR1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8242291-B2 | Process for the preparation of ramelteon | INDUSTRIALE CHIMICA S.R.L. (IT) | 2012-08-14 | — | — | US | disclosed |
| US-20120071673-A1 | SYNTHESIS OF (S)-N-[2-(1,6,7,8-TETRAHYDRO-2H-INDENO-[5,4-B]FURAN-8-YL)ETHYL]PROPIONAMIDE | LEK PHARMACEUTICALS D.D. (SI) | 2012-03-22 | — | — | US | disclosed |
| WO-2009106966-A1 | PROCESS FOR PREPARING RAMELTEON. | MEDICHEM, S.A. (ES) | 2009-09-03 | — | — | WO | disclosed |
| WO-2008151170-A2 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071673-A1 | SYNTHESIS OF (S)-N-[2-(1,6,7,8-TETRAHYDRO-2H-INDENO-[5,4-B]FURAN-8-YL)ETHYL]PROPIONAMIDE | CYP2B6, CYP2D6, CYP2A6 | MTNR1A 1049/4885MTNR1B 790/4885ABCB11 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.